This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Introduction. The Dual-Action Debate: Does Pharmacology Matter?

Michael E. Thase, MD

Published: December 15, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Major depressive disorder (MDD) is a common, often chronic, and not infrequently disabling condition. Remission has been established as the goal of short-term treatment of depression1,2 and has become the standard by which treatment efficacy is evaluated. Moreover, achieving remission early in the course of illness can lead to improved long-term outcomes.3,4 Pharmacotherapy, psychotherapy, and a combination of these approaches have been shown to be effective in the ambulatory management of MDD.’ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...